**Chai Discovery Secures $130M Series B, Valued at $1.3B**
San Francisco-based Chai Discovery, a biotech firm with notable backing from OpenAI, has successfully closed a $130 million Series B funding round, pushing its valuation to an impressive $1.3 billion. The significant capital injection is set to accelerate Chai Discovery’s mission to leverage AI in drug discovery and development.
The Series B round underscores growing investor confidence in companies at the intersection of artificial intelligence and life sciences, particularly those demonstrating innovative approaches to tackling complex biological challenges. Chai Discovery’s connection to OpenAI signals a strategic alignment with leading AI expertise, positioning the company as a key player in the rapidly evolving landscape of AI-driven biotechnology.